Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, announced the pricing of its initial public offering of 8,825,000 shares of common stock at a price to the public of $17.00 per share.